COMPASS Pathfinder Ltd.: COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors
London, UK - 1 April 2021 COMPASS Pathways plc (Nasdaq: CMPS) ( COMPASS ), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has appointed Wayne J Riley MD to its Board of Directors.
Dr Riley is President of the State University of New York (SUNY) Downstate Health Sciences University, Brooklyn, where he holds tenured professorships in internal medicine, and health policy and management. A primary care physician and an academic, he has more than 25 years of experience encompassing clinical and academic medicine, research programme oversight, biotechnology, primary care, public health, healthcare management and policy, healthcare quality, academic health science centre administration, and government service.
UK government set to lift the ban on controversial gene editing in agriculture
dailymail.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailymail.co.uk Daily Mail and Mail on Sunday newspapers.
HPU Announces Commencement Ceremony Details | High Point University
highpoint.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from highpoint.edu Daily Mail and Mail on Sunday newspapers.
EpiVario Establishes Scientific Advisory Board
Share Article
EpiVario
Bringing deep expertise in the areas of neuroscience, psychology, and epigenetics, these individuals will help EpiVario with its ongoing research efforts to utilize novel medical and scientific discoveries for the development of therapeutics for memory- and addiction-related diseases. - Dr. Berger PHILADELPHIA (PRWEB) February 16, 2021
EpiVario, Inc., a preclinical stage drug discovery and development company, today announced the formation of a Scientific Advisory Board (SAB) comprised of leading experts in neuroscience, psychology, and epigenetics. The SAB will guide and advise the Company on the translation of core discoveries into the research and development of therapeutic approaches for memory-related psychiatric disorders, including PTSD, drug and alcohol use disorder, and Alzheimer’s disease.